表紙：ナノバイオテクノロジー市場の2030年までの予測- タイプ別、治療法別、技術別、用途別、地域別の世界分析

市場調査レポート

商品コード

1358969

ナノバイオテクノロジー市場の2030年までの予測- タイプ別、治療法別、技術別、用途別、地域別の世界分析

Nanobiotechnology Market Forecasts to 2030 - Global Analysis By Type (10-100 Nm and 0-10 Nm), Therapeutic (Orthopedic Therapies, Dental Therapies, Cardiac Therapies, Liposomes and Other Therapeutics), Technology, Application and By Geography

出版日: 2023年10月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 609,303円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 770,805円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 932,307円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,101,150円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.82円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界のナノバイオテクノロジー市場は2023年に1,126億6,000万米ドルを占め、予測期間中にCAGR 7.5％で成長し、2030年には1,869億1,000万米ドルに達すると予測されています。

多くの場合、分子や微小粒子を含むナノスケールレベルの生物学的システムの研究は、ナノバイオテクノロジーとして知られ、ナノテクノロジーとバイオテクノロジー分野の融合です。ナノバイオテクノロジーと同時に使用される他の用語には、ナノ生物学とバイオナノテクノロジーがあります。100ナノメートルより小さなスケールの物質操作による材料、デバイス、システムの製造と使用は、総称して「ナノバイオテクノロジー応用」と呼ばれます。世界的に、政府や企業はナノバイオテクノロジーに多額の投資を行っています。

食糧農業機関によると、世界人口は2050年までに97億人を超えると予想されています。

慢性疾患の増加

ナノバイオテクノロジー市場の重要な成長促進要因は、世界中でがん、糖尿病、心血管疾患などの慢性疾患の有病率が上昇していることです。特定の病気に対する従来の治療法の問題点に対するより良い解決策は、ナノバイオテクノロジーによって提供されます。例えば、集中治療はナノ粒子ベースのドラッグ・デリバリー・システムによって可能になり、副作用も軽減され、患者の転帰も向上します。慢性疾患の負担が世界的に増加するにつれ、創造的なナノバイオテクノロジー・ソリューションの必要性が高まっています。

高い開発費

ナノバイオテクノロジー製品が開発され商業化されるためには、インフラ、専門機器、スタッフ、研究開発活動への多額の投資が必要となります。しかし、ナノバイオテクノロジーの高い開発費は、特に資金源が限られている新興企業や中小企業（SME）にとっては、抑止力になるかもしれないです。この障壁を突破するには、資本と投資の可能性へのアクセスが不可欠です。

ナノバイオテクノロジーへの投資の増加

臨床試験中の新規性、独創性、将来性のある製品の量の増加は、世界のナノバイオテクノロジー市場の発展を加速させると思われます。世界中の企業や政府がナノバイオテクノロジーに多額の投資を行っています。さらに、多くの政府機関がナノバイオテクノロジーの研究と進歩に投資する金額を増やしています。新規製品を市場に投入するため、企業は研究開発に積極的に投資しています。ナノバイオテクノロジー分野では、こうした革新的なツールが企業に競争上の優位性をもたらしています。

毒性と長期的影響

ナノバイオテクノロジーでは、特殊な性質と潜在的な危険性を持つナノスケールの物質を利用します。このため、規制機関はナノバイオテクノロジー製品を認証し販売する際に懸念を抱いてきました。ナノ材料の毒性や人間の健康や環境への長期的な影響に対する安全性への懸念から、監視や監視の目が厳しくなることが予想されます。したがって、予測期間中、これらの要因はナノバイオテクノロジー市場の拡大を妨げると予想されます。

COVID-19の影響：

COVID-19の流行は、効率的な薬や予防接種の創出と同様に、迅速かつ正確な診断の重要性を浮き彫りにしました。診断検査の感度と特異性を高め、ドラッグ・デリバリー・システムを強化する能力を持つナノバイオテクノロジーは、この両分野で重要な意味を持っています。ヘルスケアソリューションへの注目は、ナノバイオテクノロジー産業の拡大を加速させたかもしれないです。政府や民間投資家によって、COVID-19関連分野の研究開発に資金や資源が移された可能性があります。ウイルス関連のトピックに注力するナノバイオテクノロジー企業により多くの資金が提供された可能性があります。

予測期間中、医薬品分野が最大となる見込み

予測期間中、医薬品分野が最大のシェアを占めると予想されます。医薬品の製造と流通では、ナノスケールの材料、装置、手順が使用されます。さらに、この分野は薬の開発、送達、治療効果を変革する可能性を秘めており、さまざまな病気に対してより個別化された集中的な治療を可能にします。

予測期間中にCAGRが最も高くなると予想されるのは整形外科治療分野です。

整形外科用に特別に設計されたナノ材料、ドラッグデリバリーシステム、診断機器の開発における著しい進歩により、整形外科治療分野は予測期間中に有益な成長を遂げると予想されます。さらに、ナノ粒子やナノ複合体のようなナノ材料を使用することで、ナノバイオテクノロジーは傷ついた組織への標的ドラッグデリバリーを可能にし、治療のバイオアベイラビリティを向上させ、組織再生をサポートします。整形外科疾患の早期発見とモニタリングも、ナノスケールの画像診断法によって改善されています。

最大のシェアを占める地域

北米が予測期間中最大のシェアを占めると予想されます。安定した規制環境が、この地域のナノバイオテクノロジー開発に有利な雰囲気を作り出しています。米国のFDAやその他の規制機関は、ナノテク製品の有効性と安全性を保証するために、企業や研究者と緊密に協力しました。さらに、産業界の協力と政府の強力な支援が、この地域市場の成功の重要な要因となっています。

CAGRが最も高い地域：

臨床試験の成功と最終的な食品医薬品局（FDA）認証によってもたらされる製薬・バイオテクノロジー産業の良好な成長見通しにより、欧州が最も高い成長を遂げると予想されます。地域市場拡大の主な促進要因は、技術的に高度な製品に対する需要の高まりと、研究開発施設の充実です。地域市場の拡大に寄与すると予想されるその他の側面としては、バイオテクノロジー部門の拡大、政府の投資と取り組み、がん研究と標的医薬品、農業と環境アプリケーション、電子機器と材料におけるナノテクノロジーなどが挙げられます。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレーヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Abbott Laboratories
Advanced Nano Products Co., Ltd
Altair Nanotechnologies Inc
Biosensors International Group, Ltd
Bruker Corporation
Calando Pharmaceuticals
Celgene Corporation
Dendritic Nanotechnologies
Elan Pharmaceuticals
eSpin Technologies, Inc
Flamel Technologies
Imina Technologies SA
Johnson & Johnson
Nano Bridging Molecules SA
Novartis AG
Thermo Fisher Scientific Inc
XanTecbioanalytics GmbH

図表

List of Tables

Table 1 Global Nanobiotechnology Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Nanobiotechnology Market Outlook, By Type (2021-2030) ($MN)
Table 3 Global Nanobiotechnology Market Outlook, By 10-100 Nm (2021-2030) ($MN)
Table 4 Global Nanobiotechnology Market Outlook, By 0-10 Nm (2021-2030) ($MN)
Table 5 Global Nanobiotechnology Market Outlook, By Therapeutic (2021-2030) ($MN)
Table 6 Global Nanobiotechnology Market Outlook, By Orthopedic Therapies (2021-2030) ($MN)
Table 7 Global Nanobiotechnology Market Outlook, By Dental Therapies (2021-2030) ($MN)
Table 8 Global Nanobiotechnology Market Outlook, By Cardiac Therapies (2021-2030) ($MN)
Table 9 Global Nanobiotechnology Market Outlook, By Liposomes (2021-2030) ($MN)
Table 10 Global Nanobiotechnology Market Outlook, By Other Therapeutics (2021-2030) ($MN)
Table 11 Global Nanobiotechnology Market Outlook, By Technology (2021-2030) ($MN)
Table 12 Global Nanobiotechnology Market Outlook, By Nanoparticles (2021-2030) ($MN)
Table 13 Global Nanobiotechnology Market Outlook, By Nanoshells (2021-2030) ($MN)
Table 14 Global Nanobiotechnology Market Outlook, By Nanotubes (2021-2030) ($MN)
Table 15 Global Nanobiotechnology Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 16 Global Nanobiotechnology Market Outlook, By Application (2021-2030) ($MN)
Table 17 Global Nanobiotechnology Market Outlook, By Genomics (2021-2030) ($MN)
Table 18 Global Nanobiotechnology Market Outlook, By Drug Delivery (2021-2030) ($MN)
Table 19 Global Nanobiotechnology Market Outlook, By Proteomics (2021-2030) ($MN)
Table 20 Global Nanobiotechnology Market Outlook, By Pharmaceuticals (2021-2030) ($MN)
Table 21 Global Nanobiotechnology Market Outlook, By Food and Agriculture (2021-2030) ($MN)
Table 22 Global Nanobiotechnology Market Outlook, By Medical Devices (2021-2030) ($MN)
Table 23 Global Nanobiotechnology Market Outlook, By Medical Research (2021-2030) ($MN)
Table 24 Global Nanobiotechnology Market Outlook, By Other Applications (2021-2030) ($MN)
Table 25 North America Nanobiotechnology Market Outlook, By Country (2021-2030) ($MN)
Table 26 North America Nanobiotechnology Market Outlook, By Type (2021-2030) ($MN)
Table 27 North America Nanobiotechnology Market Outlook, By 10-100 Nm (2021-2030) ($MN)
Table 28 North America Nanobiotechnology Market Outlook, By 0-10 Nm (2021-2030) ($MN)
Table 29 North America Nanobiotechnology Market Outlook, By Therapeutic (2021-2030) ($MN)
Table 30 North America Nanobiotechnology Market Outlook, By Orthopedic Therapies (2021-2030) ($MN)
Table 31 North America Nanobiotechnology Market Outlook, By Dental Therapies (2021-2030) ($MN)
Table 32 North America Nanobiotechnology Market Outlook, By Cardiac Therapies (2021-2030) ($MN)
Table 33 North America Nanobiotechnology Market Outlook, By Liposomes (2021-2030) ($MN)
Table 34 North America Nanobiotechnology Market Outlook, By Other Therapeutics (2021-2030) ($MN)
Table 35 North America Nanobiotechnology Market Outlook, By Technology (2021-2030) ($MN)
Table 36 North America Nanobiotechnology Market Outlook, By Nanoparticles (2021-2030) ($MN)
Table 37 North America Nanobiotechnology Market Outlook, By Nanoshells (2021-2030) ($MN)
Table 38 North America Nanobiotechnology Market Outlook, By Nanotubes (2021-2030) ($MN)
Table 39 North America Nanobiotechnology Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 40 North America Nanobiotechnology Market Outlook, By Application (2021-2030) ($MN)
Table 41 North America Nanobiotechnology Market Outlook, By Genomics (2021-2030) ($MN)
Table 42 North America Nanobiotechnology Market Outlook, By Drug Delivery (2021-2030) ($MN)
Table 43 North America Nanobiotechnology Market Outlook, By Proteomics (2021-2030) ($MN)
Table 44 North America Nanobiotechnology Market Outlook, By Pharmaceuticals (2021-2030) ($MN)
Table 45 North America Nanobiotechnology Market Outlook, By Food and Agriculture (2021-2030) ($MN)
Table 46 North America Nanobiotechnology Market Outlook, By Medical Devices (2021-2030) ($MN)
Table 47 North America Nanobiotechnology Market Outlook, By Medical Research (2021-2030) ($MN)
Table 48 North America Nanobiotechnology Market Outlook, By Other Applications (2021-2030) ($MN)
Table 49 Europe Nanobiotechnology Market Outlook, By Country (2021-2030) ($MN)
Table 50 Europe Nanobiotechnology Market Outlook, By Type (2021-2030) ($MN)
Table 51 Europe Nanobiotechnology Market Outlook, By 10-100 Nm (2021-2030) ($MN)
Table 52 Europe Nanobiotechnology Market Outlook, By 0-10 Nm (2021-2030) ($MN)
Table 53 Europe Nanobiotechnology Market Outlook, By Therapeutic (2021-2030) ($MN)
Table 54 Europe Nanobiotechnology Market Outlook, By Orthopedic Therapies (2021-2030) ($MN)
Table 55 Europe Nanobiotechnology Market Outlook, By Dental Therapies (2021-2030) ($MN)
Table 56 Europe Nanobiotechnology Market Outlook, By Cardiac Therapies (2021-2030) ($MN)
Table 57 Europe Nanobiotechnology Market Outlook, By Liposomes (2021-2030) ($MN)
Table 58 Europe Nanobiotechnology Market Outlook, By Other Therapeutics (2021-2030) ($MN)
Table 59 Europe Nanobiotechnology Market Outlook, By Technology (2021-2030) ($MN)
Table 60 Europe Nanobiotechnology Market Outlook, By Nanoparticles (2021-2030) ($MN)
Table 61 Europe Nanobiotechnology Market Outlook, By Nanoshells (2021-2030) ($MN)
Table 62 Europe Nanobiotechnology Market Outlook, By Nanotubes (2021-2030) ($MN)
Table 63 Europe Nanobiotechnology Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 64 Europe Nanobiotechnology Market Outlook, By Application (2021-2030) ($MN)
Table 65 Europe Nanobiotechnology Market Outlook, By Genomics (2021-2030) ($MN)
Table 66 Europe Nanobiotechnology Market Outlook, By Drug Delivery (2021-2030) ($MN)
Table 67 Europe Nanobiotechnology Market Outlook, By Proteomics (2021-2030) ($MN)
Table 68 Europe Nanobiotechnology Market Outlook, By Pharmaceuticals (2021-2030) ($MN)
Table 69 Europe Nanobiotechnology Market Outlook, By Food and Agriculture (2021-2030) ($MN)
Table 70 Europe Nanobiotechnology Market Outlook, By Medical Devices (2021-2030) ($MN)
Table 71 Europe Nanobiotechnology Market Outlook, By Medical Research (2021-2030) ($MN)
Table 72 Europe Nanobiotechnology Market Outlook, By Other Applications (2021-2030) ($MN)
Table 73 Asia Pacific Nanobiotechnology Market Outlook, By Country (2021-2030) ($MN)
Table 74 Asia Pacific Nanobiotechnology Market Outlook, By Type (2021-2030) ($MN)
Table 75 Asia Pacific Nanobiotechnology Market Outlook, By 10-100 Nm (2021-2030) ($MN)
Table 76 Asia Pacific Nanobiotechnology Market Outlook, By 0-10 Nm (2021-2030) ($MN)
Table 77 Asia Pacific Nanobiotechnology Market Outlook, By Therapeutic (2021-2030) ($MN)
Table 78 Asia Pacific Nanobiotechnology Market Outlook, By Orthopedic Therapies (2021-2030) ($MN)
Table 79 Asia Pacific Nanobiotechnology Market Outlook, By Dental Therapies (2021-2030) ($MN)
Table 80 Asia Pacific Nanobiotechnology Market Outlook, By Cardiac Therapies (2021-2030) ($MN)
Table 81 Asia Pacific Nanobiotechnology Market Outlook, By Liposomes (2021-2030) ($MN)
Table 82 Asia Pacific Nanobiotechnology Market Outlook, By Other Therapeutics (2021-2030) ($MN)
Table 83 Asia Pacific Nanobiotechnology Market Outlook, By Technology (2021-2030) ($MN)
Table 84 Asia Pacific Nanobiotechnology Market Outlook, By Nanoparticles (2021-2030) ($MN)
Table 85 Asia Pacific Nanobiotechnology Market Outlook, By Nanoshells (2021-2030) ($MN)
Table 86 Asia Pacific Nanobiotechnology Market Outlook, By Nanotubes (2021-2030) ($MN)
Table 87 Asia Pacific Nanobiotechnology Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 88 Asia Pacific Nanobiotechnology Market Outlook, By Application (2021-2030) ($MN)
Table 89 Asia Pacific Nanobiotechnology Market Outlook, By Genomics (2021-2030) ($MN)
Table 90 Asia Pacific Nanobiotechnology Market Outlook, By Drug Delivery (2021-2030) ($MN)
Table 91 Asia Pacific Nanobiotechnology Market Outlook, By Proteomics (2021-2030) ($MN)
Table 92 Asia Pacific Nanobiotechnology Market Outlook, By Pharmaceuticals (2021-2030) ($MN)
Table 93 Asia Pacific Nanobiotechnology Market Outlook, By Food and Agriculture (2021-2030) ($MN)
Table 94 Asia Pacific Nanobiotechnology Market Outlook, By Medical Devices (2021-2030) ($MN)
Table 95 Asia Pacific Nanobiotechnology Market Outlook, By Medical Research (2021-2030) ($MN)
Table 96 Asia Pacific Nanobiotechnology Market Outlook, By Other Applications (2021-2030) ($MN)
Table 97 South America Nanobiotechnology Market Outlook, By Country (2021-2030) ($MN)
Table 98 South America Nanobiotechnology Market Outlook, By Type (2021-2030) ($MN)
Table 99 South America Nanobiotechnology Market Outlook, By 10-100 Nm (2021-2030) ($MN)
Table 100 South America Nanobiotechnology Market Outlook, By 0-10 Nm (2021-2030) ($MN)
Table 101 South America Nanobiotechnology Market Outlook, By Therapeutic (2021-2030) ($MN)
Table 102 South America Nanobiotechnology Market Outlook, By Orthopedic Therapies (2021-2030) ($MN)
Table 103 South America Nanobiotechnology Market Outlook, By Dental Therapies (2021-2030) ($MN)
Table 104 South America Nanobiotechnology Market Outlook, By Cardiac Therapies (2021-2030) ($MN)
Table 105 South America Nanobiotechnology Market Outlook, By Liposomes (2021-2030) ($MN)
Table 106 South America Nanobiotechnology Market Outlook, By Other Therapeutics (2021-2030) ($MN)
Table 107 South America Nanobiotechnology Market Outlook, By Technology (2021-2030) ($MN)
Table 108 South America Nanobiotechnology Market Outlook, By Nanoparticles (2021-2030) ($MN)
Table 109 South America Nanobiotechnology Market Outlook, By Nanoshells (2021-2030) ($MN)
Table 110 South America Nanobiotechnology Market Outlook, By Nanotubes (2021-2030) ($MN)
Table 111 South America Nanobiotechnology Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 112 South America Nanobiotechnology Market Outlook, By Application (2021-2030) ($MN)
Table 113 South America Nanobiotechnology Market Outlook, By Genomics (2021-2030) ($MN)
Table 114 South America Nanobiotechnology Market Outlook, By Drug Delivery (2021-2030) ($MN)
Table 115 South America Nanobiotechnology Market Outlook, By Proteomics (2021-2030) ($MN)
Table 116 South America Nanobiotechnology Market Outlook, By Pharmaceuticals (2021-2030) ($MN)
Table 117 South America Nanobiotechnology Market Outlook, By Food and Agriculture (2021-2030) ($MN)
Table 118 South America Nanobiotechnology Market Outlook, By Medical Devices (2021-2030) ($MN)
Table 119 South America Nanobiotechnology Market Outlook, By Medical Research (2021-2030) ($MN)
Table 120 South America Nanobiotechnology Market Outlook, By Other Applications (2021-2030) ($MN)
Table 121 Middle East & Africa Nanobiotechnology Market Outlook, By Country (2021-2030) ($MN)
Table 122 Middle East & Africa Nanobiotechnology Market Outlook, By Type (2021-2030) ($MN)
Table 123 Middle East & Africa Nanobiotechnology Market Outlook, By 10-100 Nm (2021-2030) ($MN)
Table 124 Middle East & Africa Nanobiotechnology Market Outlook, By 0-10 Nm (2021-2030) ($MN)
Table 125 Middle East & Africa Nanobiotechnology Market Outlook, By Therapeutic (2021-2030) ($MN)
Table 126 Middle East & Africa Nanobiotechnology Market Outlook, By Orthopedic Therapies (2021-2030) ($MN)
Table 127 Middle East & Africa Nanobiotechnology Market Outlook, By Dental Therapies (2021-2030) ($MN)
Table 128 Middle East & Africa Nanobiotechnology Market Outlook, By Cardiac Therapies (2021-2030) ($MN)
Table 129 Middle East & Africa Nanobiotechnology Market Outlook, By Liposomes (2021-2030) ($MN)
Table 130 Middle East & Africa Nanobiotechnology Market Outlook, By Other Therapeutics (2021-2030) ($MN)
Table 131 Middle East & Africa Nanobiotechnology Market Outlook, By Technology (2021-2030) ($MN)
Table 132 Middle East & Africa Nanobiotechnology Market Outlook, By Nanoparticles (2021-2030) ($MN)
Table 133 Middle East & Africa Nanobiotechnology Market Outlook, By Nanoshells (2021-2030) ($MN)
Table 134 Middle East & Africa Nanobiotechnology Market Outlook, By Nanotubes (2021-2030) ($MN)
Table 135 Middle East & Africa Nanobiotechnology Market Outlook, By Other Technologies (2021-2030) ($MN)
Table 136 Middle East & Africa Nanobiotechnology Market Outlook, By Application (2021-2030) ($MN)
Table 137 Middle East & Africa Nanobiotechnology Market Outlook, By Genomics (2021-2030) ($MN)
Table 138 Middle East & Africa Nanobiotechnology Market Outlook, By Drug Delivery (2021-2030) ($MN)
Table 139 Middle East & Africa Nanobiotechnology Market Outlook, By Proteomics (2021-2030) ($MN)
Table 140 Middle East & Africa Nanobiotechnology Market Outlook, By Pharmaceuticals (2021-2030) ($MN)
Table 141 Middle East & Africa Nanobiotechnology Market Outlook, By Food and Agriculture (2021-2030) ($MN)
Table 142 Middle East & Africa Nanobiotechnology Market Outlook, By Medical Devices (2021-2030) ($MN)
Table 143 Middle East & Africa Nanobiotechnology Market Outlook, By Medical Research (2021-2030) ($MN)
Table 144 Middle East & Africa Nanobiotechnology Market Outlook, By Other Applications (2021-2030) ($MN)

Product Code: SMRC23841

According to Stratistics MRC, the Global Nanobiotechnology Market is accounted for $112.66 billion in 2023 and is expected to reach $186.91 billion by 2030 growing at a CAGR of 7.5% during the forecast period. The study of biological systems at the nanoscale level, often including molecules and microscopic particles, is known as nanobiotechnology and is a blend of the nanotechnology and biotechnology fields. Other terms that are used simultaneously with nanobiotechnology include nanobiology and bionanotechnology. The production and usage of materials, devices, and systems through the manipulation of matter at scales smaller than 100 nanometers are collectively referred to as "nanobiotechnology applications. Globally, governments and businesses are investing heavily in nanobiotechnology.

According to Food & Agriculture Organization, the world population is anticipated to surpass 9.7 billion by 2050.

Market Dynamics:

Driver:

Increased incidence of chronic diseases

A significant growth driver for the nanobiotechnology market is the rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular problems, around the world. Better solutions to problems with conventional therapies for certain illnesses are provided by nanobiotechnology. For instance, focused therapy is made possible by nanoparticle-based drug delivery systems, which also reduce side effects and enhance patient outcomes. The need for creative nanobiotechnology solutions is growing as the burden of chronic diseases increases globally.

Restraint:

High development expenses

Nanobiotechnology products require large investments in infrastructure, specialized equipment, staff, and research and development activities in order to be developed and commercialized. However, nanobiotechnology's high development costs might be a deterrent, especially for startups or small and medium-sized businesses (SMEs) with restricted funding sources. To break through this barrier, access to capital and investment possibilities is essential.

Opportunity:

Increasing investments in nanobiotechnology

A rise in the quantity of novel, inventive, and promising products undergoing clinical trials will accelerate the development of the global nanobiotechnology market. Businesses and governments around the world are making significant investments in nanobiotechnology. Additionally, many government organizations have increased the amount of money that is invested in the study and advancement of nanobiotechnology. To bring novel products to market, businesses are actively investing in research and development. In the nanobiotechnology sector, these innovative tools give businesses a competitive advantage.

Threat:

Toxicity and long term impacts

Nanobiotechnology makes use of materials at the nanoscale, which have special qualities and potential hazards. Because of this, regulatory bodies have been concerned while certifying and releasing nanobiotechnology products for sale. It is anticipated that increased scrutiny and oversight will be required due to safety concerns over the toxicity and long-term impacts of nanomaterials on human health and the environment. Thus, during the course of the forecast period, these factors are anticipated to hinder the expansion of the nanobiotechnology market.

COVID-19 Impact:

The COVID-19 epidemic has highlighted the significance of quick and precise diagnosis as well as the creation of efficient medications and vaccinations. With the ability to increase the sensitivity and specificity of diagnostic tests and enhance drug delivery systems, nanobiotechnology is significant in both fields. The focus on healthcare solutions may have accelerated the expansion of the nanobiotechnology industry. Funds and resources may have been transferred by governments and private investors to research and development in COVID-19-related fields. There may have been more funding available for nanobiotechnology companies focusing on virus-related topics.

The pharmaceuticals segment is expected to be the largest during the forecast period

Pharmaceuticals segment is expected to hold largest share over the projection period. In the manufacturing and distribution of pharmaceutical products, nanoscale materials, devices, and procedures are used. Additionally, this area has the potential to transform medication development, delivery, and therapeutic efficacy, enabling more individualized and focused treatments for a range of illnesses.

The orthopedic therapies segment is expected to have the highest CAGR during the forecast period

Due to significant advances in the creation of nanomaterials, drug delivery systems, and diagnostic instruments specifically designed for orthopedic purposes, the orthopedic therapies segment is anticipated to experience profitable growth over the course of the projected period. Additionally, through the use of nanomaterials like nanoparticles and nanocomposites, nanobiotechnology enables targeted drug delivery to injured tissues, improves the bioavailability of treatments, and supports tissue regeneration. The early detection and monitoring of orthopedic disorders are also being improved by nanoscale imaging and diagnostic methods.

Region with largest share:

North America is expected to hold largest share over the projection period. A stable regulatory environment created a favorable atmosphere for the development of nanobiotechnology in the region. The FDA and other regulatory bodies in the US collaborated closely with businesses and researchers to guarantee the efficacy and safety of nanotech products. Additionally, industry collaboration and robust government support are key factors in the regional market's success.

Region with highest CAGR:

Due to favorable growth prospects for the pharmaceutical and biotechnology industries brought on by successful clinical trials and eventual Food and Drug Administration (FDA) certification, Europe is expected to have the highest growth. The main drivers of regional market expansion are the increasing demand for technologically advanced products and well-developed R&D facilities. Other aspects that are anticipated to contribute to regional market expansion include the expanding biotechnology sector, government investments and efforts, cancer research and targeted medicines, agriculture and environmental applications, and nanotechnology in electronics and materials.

Key players in the market:

Some of the key players in Nanobiotechnology market include: Abbott Laboratories, Advanced Nano Products Co., Ltd, Altair Nanotechnologies Inc, Biosensors International Group, Ltd, Bruker Corporation, Calando Pharmaceuticals, Celgene Corporation, Dendritic Nanotechnologies, Elan Pharmaceuticals, eSpin Technologies, Inc, Flamel Technologies, Imina Technologies SA, Johnson & Johnson, Nano Bridging Molecules SA, Novartis AG, Thermo Fisher Scientific Inc and XanTecbioanalytics GmbH.

Key Developments:

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes.

Types Covered:

10-100 Nm
0-10 Nm

Therapeutics Covered:

Orthopedic Therapies
Dental Therapies
Cardiac Therapies
Liposomes
Other Therapeutics

Technologies Covered:

Nanoparticles
Nanoshells
Nanotubes
Other Technologies

Applications Covered:

Genomics
Drug Delivery
Proteomics
Pharmaceuticals
Food and Agriculture
Medical Devices
Medical Research
Other Applications

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Nanobiotechnology Market, By Type

5.1 Introduction
5.2 10-100 Nm
5.3 0-10 Nm

6 Global Nanobiotechnology Market, By Therapeutic

6.1 Introduction
6.2 Orthopedic Therapies
6.3 Dental Therapies
6.4 Cardiac Therapies
6.5 Liposomes
6.6 Other Therapeutics

7 Global Nanobiotechnology Market, By Technology

7.1 Introduction
7.2 Nanoparticles
7.3 Nanoshells
7.4 Nanotubes
7.5 Other Technologies

8 Global Nanobiotechnology Market, By Application

8.1 Introduction
8.2 Genomics
8.3 Drug Delivery
8.4 Proteomics
8.5 Pharmaceuticals
8.6 Food and Agriculture
8.7 Medical Devices
8.8 Medical Research
8.9 Other Applications

9 Global Nanobiotechnology Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Abbott Laboratories
11.2 Advanced Nano Products Co., Ltd
11.3 Altair Nanotechnologies Inc
11.4 Biosensors International Group, Ltd
11.5 Bruker Corporation
11.6 Calando Pharmaceuticals
11.7 Celgene Corporation
11.8 Dendritic Nanotechnologies
11.9 Elan Pharmaceuticals
11.10 eSpin Technologies, Inc
11.11 Flamel Technologies
11.12 Imina Technologies SA
11.13 Johnson & Johnson
11.14 Nano Bridging Molecules SA
11.15 Novartis AG
11.16 Thermo Fisher Scientific Inc
11.17 XanTecbioanalytics GmbH